JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
104 hedge funds and large institutions have $194M invested in Jounce Therapeutics, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 41 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
less capital invested
Capital invested by funds: $ → $
26% less call options, than puts
Call options by funds: $1.06M | Put options by funds: $1.44M
39% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 41
Holders
104
Holding in Top 10
2
Calls
$1.06M
Puts
$1.44M
Top Buyers
| 1 | +$11.9M | |
| 2 | +$9.58M | |
| 3 | +$6.48M | |
| 4 |
BlackRock
New York
|
+$2.35M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$735K |
Top Sellers
| 1 | -$7.21M | |
| 2 | -$2.88M | |
| 3 | -$2.12M | |
| 4 |
Renaissance Technologies
New York
|
-$1.19M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$807K |